Antibiotic Treatment for Community-Acquired Pneumonia in Adults
For otherwise healthy adults with community-acquired pneumonia and no comorbidities, use amoxicillin 1 gram three times daily as first-line therapy 1.
Treatment Algorithm by Patient Category
Healthy Outpatients (No Comorbidities)
The 2019 IDSA/ATS guideline provides clear first-line options 1:
- Amoxicillin 1 g three times daily (strongest recommendation)
- Doxycycline 100 mg twice daily (alternative option)
- Macrolides (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) ONLY if local pneumococcal macrolide resistance is <25%
Important caveat: While a 2024 network meta-analysis suggested quinolones may have better clinical response rates 2, the guideline-based approach prioritizes amoxicillin due to antimicrobial stewardship concerns and the fact that most RCTs show no significant mortality differences between regimens 1.
Outpatients with Comorbidities
For patients with chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancy, or asplenia 1:
Option 1 - Combination Therapy:
- Beta-lactam: amoxicillin/clavulanate 875 mg/125 mg twice daily OR cefpodoxime 200 mg twice daily OR cefuroxime 500 mg twice daily
- PLUS macrolide (azithromycin or clarithromycin) OR doxycycline 100 mg twice daily
Option 2 - Monotherapy:
- Respiratory fluoroquinolone: levofloxacin 750 mg daily OR moxifloxacin 400 mg daily OR gemifloxacin 320 mg daily
Both approaches have strong evidence support 1. The 2024 meta-analysis supports fluoroquinolones showing trends toward lower mortality (levofloxacin p-score 0.85) 2, making them reasonable first-line monotherapy for this population.
Special Populations
Penicillin Allergy
- Use respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily, or gemifloxacin 320 mg daily)
- Alternative: doxycycline 100 mg twice daily (though less robust evidence)
- Macrolide monotherapy only if local resistance <25%
Recent Antibiotic Use (Within 3 Months)
- Avoid the same antibiotic class previously used
- Switch to respiratory fluoroquinolone if beta-lactam was used recently
- Use beta-lactam/macrolide combination if fluoroquinolone was used recently
Chronic Lung Disease (COPD, Bronchiectasis)
- Treat as "comorbidity" patient
- Preferred: Respiratory fluoroquinolone monotherapy OR beta-lactam/macrolide combination
- These patients have higher risk for resistant organisms and treatment failure
Renal Impairment
Dose adjustments required for:
- Levofloxacin: CrCl 20-49 mL/min: 750 mg loading, then 750 mg every 48 hours; CrCl 10-19 mL/min: 750 mg loading, then 500 mg every 48 hours
- Gemifloxacin: CrCl <40 mL/min: 160 mg daily (half dose)
- Amoxicillin/clavulanate: CrCl <30 mL/min: avoid 875 mg formulation; use 500 mg formulation with extended intervals
- Doxycycline: No adjustment needed (non-renal elimination)
- Azithromycin: No adjustment needed
- Moxifloxacin: No adjustment needed
Note: AKI is common in severe CAP (46% in mechanically ventilated patients) 3, so monitor renal function and adjust doses accordingly.
Key Clinical Pitfalls
Macrolide resistance: Do not use macrolide monotherapy in healthy patients if local S. pneumoniae macrolide resistance exceeds 25% 1
Fluoroquinolone overuse: While effective, reserve for appropriate indications (comorbidities, allergies) to preserve efficacy and minimize resistance development
Viral coinfection confusion: The 2025 ATS guideline recommends antibiotics even with positive viral tests in comorbid/hospitalized patients 4, but IDSA disputes this, advocating for individualized assessment 5. For outpatients with mild illness and confirmed viral infection, consider brief observation before antibiotics if clinically stable.
Amoxicillin dosing: High-dose amoxicillin (1 g three times daily) is critical—lower doses are inadequate for pneumococcal coverage, even for penicillin-intermediate strains 1
Duration: Most patients require 5-7 days of therapy if clinically improving; longer courses offer no additional benefit